Ionis Pharmaceuticals, Inc.
IONS
$72.33
-$0.01-0.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 943.71M | 966.96M | 944.05M | 717.25M | 705.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 943.71M | 966.96M | 944.05M | 717.25M | 705.14M |
| Cost of Revenue | 931.53M | 893.25M | 893.99M | 898.60M | 912.75M |
| Gross Profit | 12.18M | 73.71M | 50.07M | -181.35M | -207.61M |
| SG&A Expenses | 393.87M | 351.76M | 316.59M | 291.08M | 267.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.33B | 1.25B | 1.21B | 1.19B | 1.18B |
| Operating Income | -381.69M | -278.05M | -266.52M | -472.43M | -475.08M |
| Income Before Tax | -379.60M | -258.72M | -274.43M | -464.16M | -460.07M |
| Income Tax Expenses | 1.79M | -2.38M | -6.22M | -6.13M | -6.17M |
| Earnings from Continuing Operations | -381.39 | -256.34 | -268.22 | -458.03 | -453.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -381.39M | -256.34M | -268.22M | -458.03M | -453.90M |
| EBIT | -381.69M | -278.05M | -266.52M | -472.43M | -475.08M |
| EBITDA | -369.24M | -266.80M | -255.17M | -460.86M | -463.13M |
| EPS Basic | -2.37 | -1.61 | -1.76 | -2.99 | -3.04 |
| Normalized Basic EPS | -1.51 | -1.05 | -1.04 | -1.86 | -1.91 |
| EPS Diluted | -2.45 | -1.69 | -1.83 | -2.99 | -3.04 |
| Normalized Diluted EPS | -1.59 | -1.12 | -1.11 | -1.86 | -1.91 |
| Average Basic Shares Outstanding | 639.64M | 635.64M | 624.47M | 611.29M | 598.09M |
| Average Diluted Shares Outstanding | 662.83M | 658.83M | 647.66M | 611.29M | 598.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |